ABT (Abbott Laboratories) Beneish M-Score: -2.57 (As of Jun. 25, 2026)


ABT Abbott Laboratories ABT
80 GF Score
Price $90.49
GF Value $129.49
Valuation Significantly Undervalued
View Full Analysis

What is Abbott Laboratories Beneish M-Score?

Abbott Laboratories ABT -0.04% 80 Beneish M-Score is -2.57 as of Jun. 25, 2026. GuruFocus rates ABT with a GF Score™ of 80/100 and a GF Value™ of $129.49 (Significantly Undervalued). Among 766 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 51.31% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Abbott Laboratories's Beneish M-Score or its related term are showing as below:

ABT' s Beneish M-Score Range Over the Past 10 Years
Min: -2.82   Med: -2.59   Max: -2.04
Current: -2.57

During the past 13 years, the highest Beneish M-Score of Abbott Laboratories was -2.04. The lowest was -2.82. And the median was -2.59.


Abbott Laboratories Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Beneish M-Score Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.64 -2.66 -2.56 -2.10 -2.56

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 -2.05 -2.04 -2.56 -2.57

ABT vs SYK, MDT, BSX: Beneish M-Score Comparison

For the Medical Devices subindustry, Abbott Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Beneish M-Score falls into.


ABT
80GF Score
Abbott Laboratories ABT
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Abbott Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.089+0.528 * 0.992+0.404 * 1.1297+0.892 * 1.0659+0.115 * 1.1041
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0346+4.679 * -0.034629-0.327 * 1.3758
=-2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $11,224 Mil.
Revenue was 11164 + 11459 + 11369 + 11142 = $45,134 Mil.
Gross Profit was 6274 + 6537 + 6294 + 6288 = $25,393 Mil.
Total Current Assets was $25,508 Mil.
Total Assets was $110,429 Mil.
Property, Plant and Equipment(Net PPE) was $12,377 Mil.
Depreciation, Depletion and Amortization(DDA) was $3,163 Mil.
Selling, General, & Admin. Expense(SGA) was $13,011 Mil.
Total Current Liabilities was $18,377 Mil.
Long-Term Debt & Capital Lease Obligation was $29,638 Mil.
Net Income was 1077 + 1776 + 1644 + 1779 = $6,276 Mil.
Non Operating Income was 172 + 149 + 167 + 148 = $636 Mil.
Cash Flow from Operations was 1315 + 3315 + 2787 + 2047 = $9,464 Mil.
Total Receivables was $9,670 Mil.
Revenue was 10358 + 10974 + 10635 + 10377 = $42,344 Mil.
Gross Profit was 5890 + 6032 + 5937 + 5774 = $23,633 Mil.
Total Current Assets was $23,153 Mil.
Total Assets was $81,448 Mil.
Property, Plant and Equipment(Net PPE) was $10,932 Mil.
Depreciation, Depletion and Amortization(DDA) was $3,169 Mil.
Selling, General, & Admin. Expense(SGA) was $11,799 Mil.
Total Current Liabilities was $13,004 Mil.
Long-Term Debt & Capital Lease Obligation was $12,736 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11224 / 45134) / (9670 / 42344)
=0.248682 / 0.228368
=1.089

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(23633 / 42344) / (25393 / 45134)
=0.558119 / 0.562614
=0.992

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (25508 + 12377) / 110429) / (1 - (23153 + 10932) / 81448)
=0.656929 / 0.581512
=1.1297

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=45134 / 42344
=1.0659

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3169 / (3169 + 10932)) / (3163 / (3163 + 12377))
=0.224736 / 0.203539
=1.1041

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(13011 / 45134) / (11799 / 42344)
=0.288275 / 0.278646
=1.0346

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((29638 + 18377) / 110429) / ((12736 + 13004) / 81448)
=0.434804 / 0.31603
=1.3758

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(6276 - 636 - 9464) / 110429
=-0.034629

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Abbott Laboratories has a M-score of -2.57 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.57 mean?
Abbott Laboratories (ABT) has a Beneish M-Score of -2.57 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Abbott Laboratories and its competitors. According to the industry distribution chart, Abbott Laboratories ranks #393 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 51.3%.
Is Abbott Laboratories' Beneish M-Score too high?
Abbott Laboratories' current Beneish M-Score is -2.57. Based on the distribution chart, Abbott Laboratories ranks #393 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Beneish M-Score compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #393 out of 766 companies for Beneish M-Score. This places Abbott Laboratories in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Beneish M-Score is -2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (ABT) is currently considered Significantly Undervalued. The stock's GF Value™ is $129.49, compared to a current price of $90.49 — trading 30.1% below its estimated fair value. The current Beneish M-Score is -2.57. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Abbott Laboratories (ABT), the current Beneish M-Score is -2.57 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of $90.49 is trading 30.1% below its estimated GF Value™ of $129.49. GuruFocus considers Abbott Laboratories to be Significantly Undervalued.

Key valuation signals for ABT:

  • Beneish M-Score: -2.57
  • GF Value™: $129.49 vs. price of $90.49 (30.1% below fair value)
  • GF Score™: 80/100

No single metric tells the full story. See the ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score

Get the complete analysis for ABT

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.49
Price
$129.49
GF Value